Literature DB >> 9482534

A perspective on the clinical effectiveness and tolerance of interferon-alpha.

E C Borden1, D Parkinson.   

Abstract

Interferons (IFNs) are potent biologic response modifiers with antiviral and antiproliferative effects. The successful clinical application of IFNs for the treatment of chronic viral infections and malignancies has resulted in improved quality and quantity of life for thousands of patients, and the number of new indications for IFN therapy continues to grow. However, the therapeutic effectiveness of IFNs, including IFN-alpha, is often compromised by a variety of dose-related side effects that can be dose limiting. These side effects include flu-like symptoms, fatigue, anorexia, and depression, which may be mild or severe. A better understanding of the mechanisms by which IFN-alpha causes these side effects will facilitate the development of effective strategies to lessen their effects on the patient's quality of life and allow the maximum therapeutic dose of IFN-alpha to be administered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482534

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  19 in total

1.  The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers.

Authors:  J Bacik; M Mazumdar; B A Murphy; D L Fairclough; S Eremenco; T Mariani; R J Motzer; D Cella
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

2.  Effects of alpha-interferon on insulin-like growth factor-I, insulin-like growth factor-II and insulin-like growth factor binding protein-3 secretion by a human lung cancer cell line in vitro.

Authors:  P Del Monte; C Laurino; M Arvigo; C Palermo; F Minuto; A Barreca
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

3.  Pain, depression, and fatigue in community-dwelling adults with and without a history of cancer.

Authors:  Cielito C Reyes-Gibby; Lu Ann Aday; Karen O Anderson; Tito R Mendoza; Charles S Cleeland
Journal:  J Pain Symptom Manage       Date:  2006-08       Impact factor: 3.612

4.  A brief symptom index for advanced lung cancer.

Authors:  Susan Yount; Jennifer Beaumont; Sarah Rosenbloom; David Cella; Jyoti Patel; Thomas Hensing; Paul B Jacobsen; Karen Syrjala; Amy P Abernethy
Journal:  Clin Lung Cancer       Date:  2011-05-23       Impact factor: 4.785

5.  Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report.

Authors:  Katsuyoshi Tamaki; Akihiko Okubo
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 6.  Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C.

Authors:  Fan-Pu Ji; Zheng-Xiao Li; Hong Deng; Hong-An Xue; Yuan Liu; Min Li
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

7.  Psychological changes in melanoma patients during ipilimumab treatment compared to low-dose interferon alpha therapy-a follow-up study of first experiences.

Authors:  Péter Kovács; Gitta Pánczél; Kinga Borbola; Gabriella Juhász; Gabriella Liszkay
Journal:  Pathol Oncol Res       Date:  2014-04-27       Impact factor: 3.201

8.  A randomized trial of weekly symptom telemonitoring in advanced lung cancer.

Authors:  Susan E Yount; Nan Rothrock; Michael Bass; Jennifer L Beaumont; Deborah Pach; Thomas Lad; Jyoti Patel; Maria Corona; Rebecca Weiland; Katherine Del Ciello; David Cella
Journal:  J Pain Symptom Manage       Date:  2013-11-07       Impact factor: 3.612

Review 9.  Immunotherapy of advanced renal cell carcinoma: Current and future therapies.

Authors:  David Gill; Andrew W Hahn; Guru Sonpavde; Neeraj Agarwal
Journal:  Hum Vaccin Immunother       Date:  2016-08-05       Impact factor: 3.452

Review 10.  Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.

Authors:  Serena Slavenburg; Yvonne F Heijdra; Joost P H Drenth
Journal:  Dig Dis Sci       Date:  2009-04-28       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.